Want to see IN:VIMTALABS full AI Analyst Report?
Top Page
Vimta Labs Limited
(VIMTALABS)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹679.00
▲(11.45% Upside)
Action:Reiterated
Date:07/22/26
The score is driven primarily by strong financial quality (especially a very low-debt balance sheet and healthy profitability), supported by a favorable technical uptrend. These positives are tempered by a higher P/E and minimal dividend yield, plus some historical variability in margins and free cash flow.
Positive Factors
Low leverage / strong balance sheet
A near-zero leverage profile provides durable financial flexibility: it lowers solvency risk, supports countercyclical investment in lab capacity or technology, and preserves borrowing headroom for strategic M&A or working-capital needs, improving resilience across cycles.
Negative Factors
Margin volatility
Notable swings in gross and operating margins (including a sharp shift from very high levels to lower levels) suggest mix, pricing or cost control variability. Such volatility undermines predictability of profits and complicates multi-quarter planning and margin expansion efforts.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A near-zero leverage profile provides durable financial flexibility: it lowers solvency risk, supports countercyclical investment in lab capacity or technology, and preserves borrowing headroom for strategic M&A or working-capital needs, improving resilience across cycles.
Read all positive factors
Vimta Labs Limited (VIMTALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹27.18B
Dividend Yield0.33%
Average Volume (3M)22.50K
Price to Earnings (P/E)34.1
Beta (1Y)1.05
Revenue Growth14.22%
EPS Growth7.17%
CountryIN
Employees1,384
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)17.86
Shares Outstanding44,686,905
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Vimta Labs Limited Business Overview & Revenue Model
Company Description
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testi...
How the Company Makes Money
Vimta Labs makes money by providing fee-based outsourced services to customers that need laboratory testing and clinical/medical research work performed under applicable quality and regulatory frameworks. Its core revenue streams typically include...
Vimta Labs Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.19B | 4.07B | 3.44B | 3.18B | 3.15B | 2.76B |
| Gross Profit | 2.11B | 1.58B | 1.33B | 2.42B | 2.41B | 914.08M |
| EBITDA | 1.51B | 1.43B | 1.26B | 902.01M | 966.38M | 802.74M |
| Net Income | 796.61M | 775.12M | 673.42M | 410.09M | 481.72M | 413.30M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.62B | 4.67B | 4.00B | 3.62B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 664.70M | 670.61M | 327.21M | 256.01M | 395.73M | 112.06M |
| Total Debt | 0.00 | 33.32M | 85.15M | 191.89M | 149.88M | 193.41M |
| Total Liabilities | -4.57B | 1.05B | 876.84M | 803.54M | 805.39M | 732.14M |
| Stockholders Equity | 4.57B | 4.57B | 3.79B | 3.20B | 2.82B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | 270.48M | 489.82M | 157.66M | -156.78M | 381.32M | 203.45M |
| Operating Cash Flow | 748.73M | 1.49B | 948.30M | 608.92M | 879.37M | 590.69M |
| Investing Cash Flow | -558.92M | -1.32B | -755.37M | -760.48M | -572.56M | -378.48M |
| Financing Cash Flow | -66.76M | -98.43M | -166.81M | -19.03M | -109.81M | -166.14M |
Vimta Labs Limited Technical Analysis
Positive
609.25
Price Trends
553.84
Positive
500.71
Positive
537.24
Positive
Market Momentum
18.54
Negative
67.19
Neutral
83.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIMTALABS, the sentiment is Positive. The current price of 609.25 is above the 20-day moving average (MA) of 579.14, above the 50-day MA of 553.84, and above the 200-day MA of 537.24, indicating a bullish trend. The MACD of 18.54 indicates Negative momentum. The RSI at 67.19 is Neutral, neither overbought nor oversold. The STOCH value of 83.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIMTALABS.
Vimta Labs Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹27.18B | 34.09 | ― | 0.16% | 14.22% | 7.17% | |
76 Outperform | ₹319.77B | 58.73 | ― | 0.63% | 14.29% | 5.55% | |
73 Outperform | ₹92.18B | 33.76 | ― | 1.65% | 21.09% | 65.51% | |
72 Outperform | ₹120.82B | 63.46 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹138.06B | 79.88 | ― | 0.23% | 19.49% | 20.50% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹17.10B | 16.86 | ― | 0.51% | 7.75% | 30.21% |
* General Sector Average
IN:VIMTALABS
Vimta Labs Limited
641.20
-15.73
-2.39%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.65
-278.64
-33.12%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,888.40
311.01
19.72%
IN:METROPOLIS
Metropolis Healthcare Ltd.
588.20
82.65
16.35%
IN:THYROCARE
Thyrocare Technologies Ltd
604.40
172.84
40.05%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,384.15
314.91
29.45%
Vimta Labs Limited Corporate Events
Vimta Labs Completes Rs 2 Dividend Payout for FY 2025-26
Jul 4, 2026
Vimta Labs Limited, a Hyderabad-headquartered provider of life sciences and analytical laboratory services, operates from specialized facilities within Genome Valley and other industrial areas in Telangana. The company’s focus on quality and...
Vimta Labs Secures Shareholder Approval for All Resolutions at 36th AGM
Jun 25, 2026
Vimta Labs Limited reported that all resolutions placed before shareholders at its 36th Annual General Meeting on June 25, 2026, were duly transacted and approved. The company submitted the voting results and scrutinizer’s report to the stoc...
Vimta Labs moves to clean up shareholder records as IEPF transfers, KYC drive and special demat window advance
Apr 28, 2026
Vimta Labs has notified shareholders that unclaimed final dividends for FY 2018-19 and the corresponding equity shares will be transferred to the Investor Education and Protection Fund if not claimed by the statutory deadline, with detailed shareh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.